All News

ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3

EULAR Abstract Archive

Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS

EULAR Abstract Archive

The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9

EULAR Abstract Archive

Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7

EULAR Abstract Archive

Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8

EULAR Abstract Archive

Great talk on inflammasomes at #EULAR2020 by @dave_boucher: 4th June, 1:15pm, Ansell: Inflammasome activation in rheumatic diseases: mechanisms and perspectives for therapy @RheumNow https://t.co/HTWVxt4FMz

Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT

Preliminary definition of a +MRI for struc lesions in the SIJs in axSpA: Erosion in ≥2 consec slices or in ≥3 SIJ quad and fat lesion w depth >1cm in ≥1 SIJ quad are high priority for def an MRI struc lesion of axSpA. Abs OP0079 #EULAR2020 @RheumNow https://t.co/9RlSOUviJQ https://t.co/l4XiQDj8e4

EULAR Abstract Archive

Secukinumab in nr-axSpA, in a mostly biologic naive cohort was effective: ASAS40 response of ~42%, data from the Phase III prevent trial Abstract OP0106 #EULAR2020 @rheumnow https://t.co/KATpGJs2y9 https://t.co/zeBFS2pMl0

E-CONGRESS

And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L

#Eular2020 #op0224 filgotinib successfully reduces levels of circulating biomarkers in PsA suggestive of clinical efficacy: CRP&SAA >50%, IL6, CXCL10&IL23 >25%. Also decreased ICAM1,VCAM1, MMP1&SC1M @RheumNow

Enticing stuff. Avacopan wins on 52w remission, steroid toxicity/use, renal fx, with minimal toxicity. Looks good to be a steroid replacement in AAV, with real benefit for patients. Exciting but cost will dictate if we get to use it (see: apremilast) OP0011 #EULAR2020 @RheumNow https://t.co/WTFk21D0KY

#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status. @RheumNow https://t.co/Hkv6T7pl9f

#EULAR2020 ABST#OP0014 Plenary session: Secukinumab and etanercept do NOT work for anterior uveitis in SpA based on Swedish Rheum Quality Registry of > 2600 patients @rheumnow https://t.co/2kJ3b4JObq

#EULAR2020 ABST#OP0015Plenary session: very low serum urate < 4 mg/dL in men assc w/increased CV mortality; 40,000 pt study. NOTE: this may be driven by poorly controlled diabetes as hyperglycemia has a uricosuric effect; from NHANES database @MassGeneralNews @RheumNow https://t.co/jnhkS436JZ

#EULAR2020 Plenary Abstr#OP0016 Brilliant study showed how gut microbiota dysbiosis may trigger RA in high risk people (+CCP w/o Sx) using fecal transplantation in a mouse model to trigger collagen induced arthritis @rheumnow Healthy vs. preclin RA vs. RA microbiota specimen: https://t.co/ZITCAcmuXh

#EULAR2020 Abstr#LB001 Coming soon...another indication for @Rinvoq? Favorable response in phase III trial of upadacitinib vs. ADA vs. PCB for PsA (SELECT-PsA-1) @abbvie @rheumnow https://t.co/0udmPlR2pQ

After seeing the results of the NORD-STAR early RA trial, would you start a newly diagnosed, treatment naive RA patient on: #EULAR2020 @RheumNow

Best advice by Dr. R Landewe @EULAR2020 "Do NOT lose contact with your patients during the pandemic!" Many patients are fearful and will not reach out to their physicians; don't let them get lost in the shuffle. @rheumnow https://t.co/FAkEYexsGo

#EULAR2020 OP0020: RABBIT 5500 pt study of all DMARDS/biologics, IL-6 inh may be the best to improve fatigue seen in RA patients @rheumnow https://t.co/VJW8MwMamM

Topics

All News

Do you get our email newsletter?